DSM Nutritional Products to Release New Technology at CPhI
The company will be releasing its new 3C technology for omega 3 EPA and DHA at CPhI Worldwide.
On July 27, 2016, DSM Nutritional Products announced that it will be introducing its 3C technology for omega-3 EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) at CPhI Worldwide 2016. The 3C technology delivers highly concentrated and customizable combinations of EPA and DHA for both pharmaceutical and food supplement applications. Visitors to DSM Nutritional Products at stand S310 during CPhI can learn about the omega-3 EPA/DHA status in individual countries. Prototypes will be available to demonstrate how the high EPA/DHA concentrations offered by 3C technology make it possible to achieve a much smaller capsule size.
Source: DSM Nutritional Products
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
